Skip to main content
https://www.highperformancecpmgate.com/rgeesizw1?key=a9d7b2ab045c91688419e8e18a006621

Johnson & Johnson partners with BARDA to fund $1 billion in COVID-19 vaccine research

Pharmaceutical giant Johnson & Johnson is partnering with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services to fund over $1 billion in COVID-19 vaccine and antiviral treatment research and development, the company said on Monday.

The partnership is an expansion of an existing agreement between BARDA and J&J’s Janssen Pharmaceutical Companies division.

With the agreement, the company is setting a goal of providing a global supply of more than one billion doses of the vaccine, which J&J expects to have in clinical trials by September 2020 at the latest. The first batches of the vaccine may be available for emergency use by early 2021, the company said.

BARDA’s partnership with J&J encompasses research and development of potential antiviral treatments in addition to the work that’s being done to develop a vaccine for the disease. Those efforts include development work J&J and BARDA are conducting with the Rega Institute for Medical Research in Belgium.

J&J said it had also committed to expanding its global manufacturing capacity, both in the U.S. and overseas. That additional production ability will help the company bring an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use, the company said.

Working with teams at Beth Israel Deaconess Medical Center, a part of the Harvard Medical School, Janssen Pharmaceuticals began its research into potential vaccine candidates back in January. Those candidates were tested at several academic institutions, the company said, which led to the identification of a lead COVID-19 vaccine candidate — and two potential back-ups.

Last week, Moderna Health, another pharmaceutical company working on a vaccine, said that it could have an experimental treatment available to healthcare workers as soon as the fall.

Moderna could make experimental COVID-19 vaccine available to healthcare workers by fall

The Moderna vaccine uses messenger RNA, rather than doses of the COVID-19 virus itself, to inoculate against the disease. The use of mRNA means that the inoculation doesn’t expose recipients to the disease itself, so they’re not at risk of contracting the disease.

Last Monday, Moderna made the vaccine available to volunteer participants as part of the company’s Phase 1 clinical trials conducted in Washington state.

Comments

Post a Comment

Popular posts from this blog

Uber co-founder Garrett Camp steps back from board director role

Uber co-founder Garrett Camp is relinquishing his role as a board director and switching to board observer — where he says he’ll focus on product strategy for the ride hailing giant. Camp made the announcement in a short Medium post in which he writes of his decade at Uber: “I’ve learned a lot, and realized that I’m most helpful when focused on product strategy & design, and this is where I’d like to focus going forward.” “I will continue to work with Dara [Khosrowshahi, Uber CEO] and the product and technology leadership teams to brainstorm new ideas, iterate on plans and designs, and continue to innovate at scale,” he adds. “We have a strong and diverse team in place, and I’m confident everyone will navigate well during these turbulent times.” The Canadian billionaire entrepreneur signs off by saying he’s looking forward to helping Uber “brainstorm the next big idea”. Camp hasn’t been short of ideas over his career in tech. He’s the co-founder of the web 2.0 recommendatio...
Post a Comment
Read more

Drone crash near kids leads Swiss Post and Matternet to suspend autonomous deliveries

A serious crash by a delivery drone in Switzerland have grounded the fleet and put a partnership on ice. Within a stone’s throw of a school, the incident raised grim possibilities for the possibilities of catastrophic failure of payload-bearing autonomous aerial vehicles. The drones were operated by Matternet as part of a partnership with the Swiss Post (i.e. the postal service), which was using the craft to dispatch lab samples from one medical center for priority cases. As far as potential applications of drone delivery, it’s a home run — but twice now the craft have crashed, first with a soft landing and the second time a very hard one. The first incident, in January, was the result of a GPS hardware error; the drone entered a planned failback state and deployed its emergency parachute, falling slowly to the ground. Measures were taken to improve the GPS systems. The second failure in May, however, led to the drone attempting to deploy its parachute again, only to sever the line...
Post a Comment
Read more

How the world’s largest cannabis dispensary avoids social media restrictions

Planet 13 is the world’s largest cannabis dispensary. Located in Las Vegas, blocks off the Strip, the facility is the size of a small Walmart. By design, it’s hard to miss. Planet 13 is upending the dispensary model. It’s big, loud and visitors are encouraged to photograph everything. As part of the cannabis industry, Planet 13 is heavily restricted on the type of content it can publish on Instagram, Facebook and other social media platforms. It’s not allowed to post pictures of buds or vapes on some sites. It can’t talk about pricing or product selection on others.   View this post on Instagram   A post shared by Morgan Celeste SF Blogger (@bayareabeautyblogger) on Jan 25, 2020 at 7:54pm PST Instead, Planet 13 encourages its thousands of visitors to take photos and videos. Starting with the entrance, the facility is full of surprises tailored for the ‘gram. As a business, Planet 13’s social media content is heavily restricted a...
3 comments
Read more